|1.||Felix, Stephan B: 2 articles (10/2009 - 09/2007)|
|2.||Kieback, Arne Georg: 1 article (10/2009)|
|3.||Reffelmann, Thorsten: 1 article (10/2009)|
|4.||Lausević-Vuk, Ljiljana: 1 article (09/2008)|
|5.||Kieback, Arne G: 1 article (09/2007)|
|6.||Grohmann, Andrea: 1 article (09/2007)|
|7.||Baumann, Gert: 1 article (09/2007)|
|8.||Takasu, Rie: 1 article (06/2003)|
|9.||Takemura, Genzou: 1 article (06/2003)|
|10.||Muraoka, Isao: 1 article (06/2003)|
05/01/1992 - "These data suggest that quinaprilat produces possible venodilation through immediately improved total body vascular compliance thereby reducing cardiac preload in this rat model of chronic heart failure."
11/01/1996 - "The study results obtained in patients with advanced heart failure support both the safety and favorable hemodynamic and neurohumoral effects of intravenous quinaprilat over an observation period of 3 days."
09/01/2008 - "In prevention of heart failure in patients with impaired left ventricle function (LVEF<30%), who had undergone CABG surgery with use of cardiopulmonaly bypass, we achieved the best effects on the hemodynamics with parenteral administration of quinaprilat."
11/01/1996 - "[Hemodynamic and humoral effects of parenteral therapy with intravenously administered ACE inhibitor quinaprilat in patients with advanced heart failure]."
06/01/1996 - "Single and multiple intravenous doses of 0.5 to 10 mg quinaprilat are well-tolerated and produce favorable dose-dependent hemodynamic effects and hormonal changes consistent with those expected of an ACE inhibitor in patients with NYHA class III and IV congestive heart failure."
|2.||Renal Insufficiency (Renal Failure)
04/01/1992 - "In contrast, quinaprilat maximum plasma concentration, trough and peak steady-state plasma concentrations, area under the plasma concentration-time curve, and half-life increased significantly with increasing renal insufficiency. "
04/01/1992 - "The renal clearance of quinapril and quinaprilat decreased with increasing renal insufficiency but did not result in significant changes in quinapril pharmacokinetics in patients with renal impairment. "
06/01/2003 - "Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis."
01/01/1993 - "Pharmacokinetics and pharmacodynamics of quinaprilat after low dose quinapril in patients with terminal renal failure."
08/01/1990 - "1. The pharmacokinetics and pharmacodynamics of quinapril and its active metabolite quinaprilat were studied in 20 subjects with renal function varying from normal to severe renal failure, during the approach to and at steady-state, and for 72 h after cessation of quinapril 20 mg orally for 7 days. "
07/01/2001 - "In the present study, we electrophysiologically investigated PAC function in intact endothelium of aorta (EA) and mesenteric artery (EMA) from stroke-prone spontaneously hypertensive rats (SHRSP), SHRSP after 4 weeks of treatment with quinaprilat (10 mg/kg/day), and normotensive Wistar-Kyoto (WKY) rats. "
08/01/2002 - "All treatments substantially improved postischemic recovery of external heart work (62% +/- 6%, 69% +/- 3%, and 64% +/- 5% in quinaprilat during cardioplegia, quinaprilat during reperfusion, and l-arginine groups, respectively, vs 35% +/- 5% in control group, P <.001) with similarly increased external stroke work and cardiac output. "
08/01/2002 - "When administered during ischemia, quinaprilat significantly improved recovery of coronary flow (70% +/- 8%, P =.028 vs quinaprilat during reperfusion [49% +/- 5%] and P =.023 vs control [48% +/- 6%]). "
06/01/2003 - "Quinaprilat did not affect the myocardial interstitial 2,5-DHBA level but significantly increased the NOx level during ischemia and reperfusion. "
08/01/2002 - "Ultrastructural grading of mitochondrial damage revealed best preservation with quinaprilat during ischemia (100% [no damage], P =.001 vs control). "
06/15/1999 - "ACE inhibition with quinaprilat promotes angiogenesis in a rabbit model of hindlimb ischemia. "
10/01/1999 - "Myocardial blood flow was analyzed in ischemic and nonischemic regions of 10 symptomatic patients with coronary artery disease using repetitive [15O] water positron emission tomography at rest and during maximal dobutamine stress before and after ACE inhibition with quinaprilat 10 mg i.v. To exclude the possibility that repetitive ischemia may cause an increase in MBF, eight patients underwent the same protocol without quinaprilat (placebo patients). "
03/01/1992 - "These data suggest that quinaprilat produces possible venodilation through improved total body vascular compliance, thereby reducing cardiac preload in this rat model of myocardial infarction."
05/01/1992 - "Quinaprilat increases total body vascular compliance in rats with myocardial infarction."
03/01/1992 - "Quinaprilat increases total body vascular compliance in rats with myocardial infarction."
06/01/2003 - "Quinaprilat reduces myocardial infarct size involving NO production and mitochondrial KATP channels in rabbits without collateral circulation."
06/01/2003 - "Quinaprilat reduces myocardial infarct size involving nitric oxide production and mitochondrial KATP channel in rabbits."
|6.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|8.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|1.||Induced Heart Arrest (Cardioplegia)
|2.||Blood Component Removal (Apheresis)
|4.||Continuous Ambulatory Peritoneal Dialysis (CAPD)